Dermatology
Conference Coverage
Several uncommon skin disorders related to internal diseases reviewed
Dermatologist discusses sarcoidosis, Rosai-Dorfman disease, Erdheim-Chester disease, and more.
News from the FDA/CDC
FDA approves intravenous immunoglobulin for dermatomyositis
Octagam 10% is the first treatment to have an indication specifically for dermatomyositis.
Feature
Recent trend: Melanoma mortality declining rapidly
Annual report on the status of cancer shows that the incidence of melanoma has been steadily increasing.
Opinion
A healthy family who had been living in Brazil presented with crusted plaques on their extremities
A family of 3 who had recently been in Colombia and Panama presented with asymptomatic crusted plaques on their extremities.
Latest News
Stop using Neutrogena and Aveeno spray sunscreen, J&J warns
Consumers should stop using these products and throw them away, the company said.
Latest News
Proposed classification framework for atopic dermatitis unveiled
“There are some patients who have milder-looking lesions, but their itch is just out of control. ... This is a pattern that we need to recognize...
From the Journals
Metformin use may curb BCC risk
Population-based study shows a potential protective effect of metformin use for basal cell carcinoma, but no effect on risk of squamous cell...
News
Latest FDA pembrolizumab approval expands label to cutaneous SCCs
The objective response rate in 54 patients with locally advanced disease was 50%, including a complete response rate of 17% and a partial response...
Conference Coverage
Patients on methotrexate show T-cell response to Pfizer vaccine
Despite poor antibody response to the mRNA COVID-19 vaccine, cellular immunity was generated in patients taking methotrexate, new research shows...
From the Journals
New analysis puts U.S. psoriasis prevalence at 3%
Data from national survey show that no significant change in prevalence has occurred since 2003.
Conference Coverage
Expert shares practical considerations when prescribing dupilumab
Real-world data suggests that the effectiveness of dupilumab is similar to the efficacy seen in clinical trials.